Brought to you by 
Merck KGAA pays €20mm up front for exclusive rights to Symphogen’s Sym004; rights returned
30 Mar 2021
Executive Summary
Symphogen AS (therapies for autoimmune and infectious diseases and cancer) has granted Merck KGAA exclusive worldwide rights to develop and sell its lead project Sym004, an antibody mixture in Phase I/II trials for advanced KRAS wild-type metastatic colorectal cancer patients, who have previously responded to treatment with standard chemo and a marketed anti-EGFR monoclonal antibody.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck KGAA pays €20mm up front for exclusive rights to Symphogen’s Sym004; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice